专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

101. 发明申请

WO2005038057A1 CLASSIFICATION OF PATIENTS HAVING DIFFUSE LARGE B-CELL LYMPHOMA BASED UPON GENE EXPRESSION 审中-公开
标题翻译：基于基因表达的患有DIFFUSE大型B细胞淋巴瘤患者的分类
公开(公告)号：WO2005038057A1
公开(公告)日：2005-04-28
申请号：PCT/US2004/034874
申请日：2004-10-11
申请人： APPLERA CORPORATION , LEVY, Ronald , WECHSER, Mark A. , LOSSOS, Izidore S. , TIBSHIRANI, Robert J. , ALIZADEH, Ash A. , BOTSTEIN, David
发明人： LEVY, Ronald , WECHSER, Mark A. , LOSSOS, Izidore S. , TIBSHIRANI, Robert J. , ALIZADEH, Ash A. , BOTSTEIN, David
IPC分类号： C12Q1/68
CPC分类号： G01N33/57426 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/16
摘要： Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival.
摘要翻译：公开了基于多个基因的表达来分类具有弥漫性大B细胞淋巴瘤（DLBCL）的患者的方法和试剂盒。实时定量RT-PCR可用于测量表达值。将来自患者的肿瘤样品中的多个基因的表达值与从DLBCL患者获得的参照表达值相关联可以对分类组中的患者进行分层。方法和试剂盒可用于预测总体患者生存。

102. 发明申请

WO2005015235A1 METHOD FOR DETECTING LOW LEVELS OF A FUSION PROTEIN 审中-公开
标题翻译：检测融合蛋白低水平的方法
公开(公告)号：WO2005015235A1
公开(公告)日：2005-02-17
申请号：PCT/NL2004/000562
申请日：2004-08-11
申请人： ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM , STAAL, Frank, Jakob, Theodor , VAN DONGEN, Jacobus, Johannes, Maria
发明人： STAAL, Frank, Jakob, Theodor , VAN DONGEN, Jacobus, Johannes, Maria
IPC分类号： G01N33/574
CPC分类号： G01N33/57426 , G01N33/54306 , G01N33/57484
摘要： The invention relates to the detection of among others tumor-specific fusion proteins. Provided is a method for detecting a fusion protein in a sample, said fusion protein comprising an amino-terminal fragment and a carboxy-terminal fragment which are each corresponding to a native protein, said method comprising contacting said sample with at least one binding molecule specifically reactive with a part of the native protein that is not present in the fusion protein, under conditions that allow for the formation of a complex between said at least one binding molecule and said native protein, removing said complex from said sample to deplete said sample of said native protein but not of said fusion protein; and detecting said fusion protein in said sample using at least one antibody probe directed against said fusion protein. Also provided is a diagnostic kit for carrying out a method of the invention.
摘要翻译：本发明涉及其他肿瘤特异性融合蛋白的检测。提供了一种用于检测样品中融合蛋白的方法，所述融合蛋白包含氨基末端片段和羧基末端片段，其各自对应于天然蛋白质，所述方法包括使所述样品与至少一种结合分子特异性地接触在允许在所述至少一个结合分子和所述天然蛋白质之间形成复合物的条件下，与所述融合蛋白中不存在的天然蛋白质的一部分反应，从所述样品中除去所述复合物以将所述样品去除所述天然蛋白质，但不是所述融合蛋白质; 以及使用针对所述融合蛋白的至少一个抗体探针检测所述样品中的所述融合蛋白。还提供了用于实施本发明的方法的诊断试剂盒。

103. 发明申请

WO2004029575A3 METHODS FOR DIAGNOSING HTLV-I-MEDIATED DISEASES 审中-公开
标题翻译：诊断HTLV-I介导的疾病的方法
公开(公告)号：WO2004029575A3
公开(公告)日：2004-09-23
申请号：PCT/US0315281
申请日：2003-05-16
申请人： EASTERN VIRGINIA MED SCHOOL , SEMMES OLIVER JOHN IV , WRIGHT GEORGE L JR , WARD MICHAEL D
发明人： SEMMES OLIVER JOHN IV , WRIGHT GEORGE L JR , WARD MICHAEL D
IPC分类号： G01N33/483 , C07K14/47 , C07K16/18 , C12N15/09 , C12Q1/68 , G01N20060101 , G01N33/53 , G01N33/567 , G01N33/569 , G01N33/574 , G01N33/68
CPC分类号： G01N33/57426 , G01N33/56988 , G01N2333/15 , G01N2333/805 , G01N2333/8125
摘要： Protein biomarkers that may advantageously be utilized in aiding in, or making, a diagnosis of HTLV-I-associated myelopathy (HAM), adult T-cell leukemia (ATL) or a negative diagnosis are described. Accordingly, in one aspect of the invention, methods for aiding in, or otherwise making, a diagnosis of ATL, HAM or a negative diagnosis are provided. Methods of detecting the protein biomarkers, kits that may be utilized to detect the biomarkers, as well as isolated protein biomarkers are also provided.
摘要翻译：描述可有利地用于帮助或制定HTLV-1相关的脊髓病（HAM），成人T细胞白血病（ATL）或阴性诊断的蛋白质生物标志物。因此，在本发明的一个方面中，提供了用于辅助或以其他方式进行ATL，HAM或阴性诊断的诊断的方法。还提供了检测蛋白质生物标志物的方法，可用于检测生物标志物的试剂盒以及分离的蛋白质生物标志物。

104. 发明申请

WO2004074321A2 NOVEL THERAPEUTIC GPCR TARGETS IN CANCER 审中-公开
标题翻译：癌症中新的治疗GPCR目标
公开(公告)号：WO2004074321A2
公开(公告)日：2004-09-02
申请号：PCT/US2004005000
申请日：2004-02-17
申请人： SAGRES DISCOVERY INC , MORRIS DAVID W , MALANDRO MARC S
发明人： MORRIS DAVID W , MALANDRO MARC S
IPC分类号： A61K39/00 , C07K14/47 , C12Q1/68 , G01N33/574
CPC分类号： G01N33/57426 , A61K39/00 , C07K14/4748 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/57492 , Y02A90/26
摘要： The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. This invention relates to G-protein coupled receptor (GPCR) sequences. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.
摘要翻译：本发明涉及用于癌症尤其是淋巴瘤的检测，诊断和治疗的新型序列。本发明提供癌症相关（CA）多核苷酸序列，其表达与癌症相关。本发明提供了存在于细胞表面上的与癌症相关的CA多肽，并提出了针对癌症的新型治疗靶点。本发明涉及G蛋白偶联受体（GPCR）序列。本发明还提供了用于检测癌症的诊断组合物和方法。本发明提供对CA多肽具有特异性的单克隆和多克隆抗体。本发明还提供用于癌症的筛选，预防和治疗的诊断工具和治疗组合物和方法。

105. 发明申请

WO2004074320A2 NOVEL THERAPEUTIC TARGETS IN CANCER 审中-公开
标题翻译：癌症中新的治疗靶点
公开(公告)号：WO2004074320A2
公开(公告)日：2004-09-02
申请号：PCT/US2004/004730
申请日：2004-02-17
申请人： SAGRES DISCOVERY, INC. , MORRIS, David, W. , MORRIS, David, W. , MALANDRO, Marc, S.
发明人： MORRIS, David, W. , MORRIS, David, W. , MALANDRO, Marc, S.
IPC分类号： C07K14/47
CPC分类号： G01N33/57492 , A61K39/00 , C07K14/4748 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/57426
摘要： The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that are present on the cell surface and present novel therapeutic targets against cancer. The present invention further provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.
摘要翻译：本发明涉及用于检测，诊断和治疗癌症，特别是淋巴瘤的新型序列。本发明提供了表达与癌症相关的癌症相关（CA）多核苷酸序列。本发明提供了与癌症相关的CA多肽，其存在于细胞表面上并且呈现针对癌症的新型治疗靶标。本发明进一步提供了用于检测癌症的诊断组合物和方法。本发明提供了对CA多肽特异性的单克隆和多克隆抗体。本发明还提供了用于筛选，预防和治疗癌症的诊断工具和治疗组合物和方法。

106. 发明申请

WO2004058146A2 NOVEL COMPOSITIONS AND METHODS IN CANCER 审中-公开
标题翻译：癌症中的新型组合物和方法
公开(公告)号：WO2004058146A2
公开(公告)日：2004-07-15
申请号：PCT/US2003/040081
申请日：2003-12-15
申请人： SAGRES DISCOVERY, INC. , MORRIS, David, W. , MALANDRO, Marc, S.
发明人： MORRIS, David, W. , MALANDRO, Marc, S.
IPC分类号： A61K
CPC分类号： C07K14/82 , C07K14/4748 , C12Q1/6886 , C12Q2600/136 , G01N33/5023 , G01N33/57415 , G01N33/57426 , G01N33/57434 , G01N33/5748
摘要： The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer and provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.
摘要翻译：本发明涉及用于检测，诊断和治疗癌症，特别是淋巴瘤的新型序列。本发明提供了表达与癌症相关的癌症相关（CA）多核苷酸序列。本发明提供了与癌症相关的CA多肽，并提供了用于检测癌症的诊断组合物和方法。本发明提供了对CA多肽特异性的单克隆和多克隆抗体。本发明还提供了用于筛选，预防和治疗癌症的诊断工具和治疗组合物和方法。

107. 发明申请

WO2004049917A2 METHODS OF THERAPY AND DIAGNOSIS USING TARGETING OF CELLS THAT EXPRESS LY-9 审中-公开
标题翻译：使用LY-9表达细胞的方法治疗和诊断方法
公开(公告)号：WO2004049917A2
公开(公告)日：2004-06-17
申请号：PCT/US2003/038364
申请日：2003-12-01
申请人： NUVELO, INC. , EMTAGE, Peter, C., R.
发明人： EMTAGE, Peter, C., R.
IPC分类号： A61B
CPC分类号： C07K16/30 , A61K47/6849 , A61K2039/505 , C07K16/2803 , G01N33/57426
摘要： Targeting of Ly-9 expressing cells using targeting compounds such as Ly-9 polypeptides, nucleic acids encoding for Ly-9 polypeptides and anti-Ly-9 antibodies provides a method of killing or inhibiting growth of said cells that may be useful in treating diseases including cancer. Methods of therapy and diagnosis of disorders associated with Ly-9-protein-expressing cells are described.
摘要翻译：使用靶向化合物如Ly-9多肽，编码Ly-9多肽的核酸和抗-ly-9抗体靶向Ly-9表达细胞提供了可用于治疗疾病的所述细胞生长的方法包括癌症。描述了与Ly-9蛋白表达细胞相关的病症的治疗和诊断方法。

108. 发明申请

WO2003097097A1 VLA4アンタゴニストを含む治療用医薬組成物を用いた急性白血病の治療および/または再発予防方法ならびにVLA4を指標とした急性白血病の予後の診断方法审中-公开
标题翻译：使用含有VLA4拮抗剂的治疗药物组合物治疗和/或预防急性白血病的方法以及使用VLA4作为指示诊断急性淋巴细胞白血病的方法
公开(公告)号：WO2003097097A1
公开(公告)日：2003-11-27
申请号：PCT/JP2002/004704
申请日：2002-05-15
申请人：新津洋司郎 , 松永卓也 , 三宅健介 , 坂牧純夫 , 秋山剛英 , 藤見章仁 , 田中育太 , 竹本尚史
发明人：新津洋司郎 , 松永卓也 , 三宅健介 , 坂牧純夫 , 秋山剛英 , 藤見章仁 , 田中育太 , 竹本尚史
IPC分类号： A61K45/00
CPC分类号： G01N33/57426 , C07K16/2842
摘要： Medicinal compositions for treating acute leukemia whereby the interaction between fibronectin and VLA4 is inhibited by using a VLA4 antagonist to thereby regulate the acquisition of cell adhesion-depending anticancer agent-tolerance by leukemic cells; a method of treating and/or preventing acute leukemia using these compositions; and a method of diagnosing acute leukemia based on the VLA4 expression ratio in acute leukemic cells.
摘要翻译：用于治疗急性白血病的药物组合物，由此通过使用VLA4拮抗剂来抑制纤连蛋白和VLA4之间的相互作用，从而调节白血病细胞获得细胞粘附依赖性抗癌剂耐受性; 使用这些组合物治疗和/或预防急性白血病的方法; 以及基于急性白血病细胞中VLA4表达比例诊断急性白血病的方法。

109. 发明申请

WO2003089927A2 ANTIGENS ASSOCIATED WITH HAEMATOLOGICAL MALIGNANCY 审中-公开
标题翻译：与血液恶性肿瘤相关的抗原
公开(公告)号：WO2003089927A2
公开(公告)日：2003-10-30
申请号：PCT/GB2003/001651
申请日：2003-04-16
申请人： KINGS' COLLEGE LONDON , GUINN, Barbara
发明人： GUINN, Barbara
IPC分类号： G01N33/53
CPC分类号： C07K14/4748 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N33/57426
摘要： This invention relates to the identification of antigens (herein termed GKT-AML8, GKT-AML10 and GKT-AML12) whose expression is associated with haematological malignancy, in particular leukaemia. These antigens are useful in the diagnosis and treatment of haematological malignancies, including acute myeloid leukaemia.
摘要翻译：本发明涉及其表达与血液恶性肿瘤特别是白血病相关的抗原（本文称为GKT-AML8，GKT-AML10和GKT-AML12）的鉴定。这些抗原可用于诊断和治疗血液恶性肿瘤，包括急性骨髓性白血病。

110. 发明申请

WO2003084480A2 HAUSP-p53 INTERACTION AND USES THEREOF 审中-公开
标题翻译： HAUSP-p53相互作用及其用途
公开(公告)号：WO2003084480A2
公开(公告)日：2003-10-16
申请号：PCT/US2003/009639
申请日：2003-03-28
申请人： THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
发明人： GU, Wei , LI, Muiyang
IPC分类号： A61K
CPC分类号： G01N33/57484 , A61K38/1709 , C12Q1/6886 , C12Q2600/156 , C12Q2600/158 , G01N33/57426
摘要： The present invention provides methods for determining whether a subject has neoplasia, methods for assessing the efficacy of therapy to treat neoplasia in a subject, methods for assessing the prognosis of a subject who has neoplasia, and methods for treating neoplasia in a subject in need of treatment. The present invention further provides a kit for use in detecting neoplasia. Additionally, the present invention provides a pharmaceutical composition, comprising a modulator of HAUSP expression or a HAUSP protein and a pharmaceutically acceptable carrier. Also provided is a method for deubiquitinating p53 in a cell. The present invention is further directed to a method for identifying an agent that is reactive with p53, and the agent identified by this method. Furthermore, the present invention provides a method for treating a p53-associated condition in a subject in need of treatment. The present invention is also directed to a complex comprising p53 and HAUSP, and a mutant protein comprising the HAUSP amino acid sequence, in which Ser is substituted for Cys at amino acid residue 223. Finally, the present invention provides a transgenic non-human animal whose genome comprises a disruption in its endogenous HAUSP gene.
摘要翻译：本发明提供了用于确定受试者是否具有瘤形成的方法，用于评估治疗对受试者的瘤形成的疗效的方法，用于评估患有瘤形成的受试者的预后的方法以及在需要治疗的受试者中治疗瘤形成的方法治疗。本发明还提供了用于检测瘤形成的试剂盒。另外，本发明提供了包含HAUSP表达调节剂或HAUSP蛋白质和药学上可接受的载体的药物组合物。还提供了在细胞中去泛素化p53的方法。本发明还涉及用于鉴定与p53反应的药剂的方法，以及通过该方法鉴定的药剂。此外，本发明提供了治疗需要治疗的受试者中p53相关病症的方法。本发明还涉及包含p53和HAUSP的复合物，以及包含HAUSP氨基酸序列的突变蛋白，其中Ser被氨基酸残基223替代Cys。最后，本发明提供了一种转基因非人动物其基因组包含其内源性HAUSP基因的破坏。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式